Rocket Pharmaceuticals (RCKT) to Release Quarterly Earnings on Monday

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) will likely be announcing its earnings results before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $0.03 million for the quarter.

Rocket Pharmaceuticals Stock Performance

NASDAQ RCKT traded down $0.05 during trading on Thursday, reaching $10.87. 867,224 shares of the company's stock were exchanged, compared to its average volume of 1,451,576. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The business has a 50 day moving average price of $11.17 and a 200-day moving average price of $15.15. The stock has a market capitalization of $990.91 million, a P/E ratio of -3.95 and a beta of 0.98. Rocket Pharmaceuticals has a fifty-two week low of $9.33 and a fifty-two week high of $31.47.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Leerink Partners decreased their target price on Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, November 19th. Canaccord Genuity Group reiterated a "buy" rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Jefferies Financial Group assumed coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, December 18th. They set a "buy" rating and a $29.00 target price for the company. Finally, Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a report on Monday, December 30th. They issued an "outperform" rating and a $32.00 price target on the stock. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Rocket Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $47.27.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.